These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18481916)

  • 21. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
    De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
    Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW; Cohen ML
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.
    Odagaki Y; Kinoshita M; Ota T
    J Psychopharmacol; 2016 Sep; 30(9):896-912. PubMed ID: 27464743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.
    Thomsen M; Fulton BS; Caine SB
    Psychopharmacology (Berl); 2014 Feb; 231(3):469-79. PubMed ID: 23995301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine.
    Li Z; Snigdha S; Roseman AS; Dai J; Meltzer HY
    Eur J Pharmacol; 2008 Oct; 596(1-3):89-97. PubMed ID: 18771666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrine-xanomeline and tacrine-iperoxo hybrid ligands: Synthesis and biological evaluation at acetylcholinesterase and M
    Maspero M; Volpato D; Cirillo D; Yuan Chen N; Messerer R; Sotriffer C; De Amici M; Holzgrabe U; Dallanoce C
    Bioorg Chem; 2020 Mar; 96():103633. PubMed ID: 32032848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
    Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
    Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
    Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
    Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of M3 muscarinic receptor regulation by wash-resistant xanomeline binding.
    Noetzel MJ; Grant MK; El-Fakahany EE
    Pharmacology; 2009; 83(5):301-17. PubMed ID: 19401618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
    Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biased Profile of Xanomeline at the Recombinant Human M
    McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
    ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.
    Sabb AL; Husbands GM; Tokolics J; Stein RP; Tasse RP; Boast CA; Moyer JA; Abou-Gharbia M
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1895-900. PubMed ID: 10450949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS
    J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.
    Fang L; Jumpertz S; Zhang Y; Appenroth D; Fleck C; Mohr K; Tränkle C; Decker M
    J Med Chem; 2010 Mar; 53(5):2094-103. PubMed ID: 20158205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of memory function in aged mice by a novel derivative of xanomeline.
    Cui Y; Wang D; Si W; Lv W; Niu Y; Lei X; Hu Y; Cao X
    Cell Res; 2008 Nov; 18(11):1151-3. PubMed ID: 18936783
    [No Abstract]   [Full Text] [Related]  

  • 38. Bitopic Binding Mode of an M
    Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
    Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of M
    Cadeddu R; Braccagni G; Branca C; van Luik ER; Pittenger C; Thomsen MS; Bortolato M
    Br J Pharmacol; 2024 Sep; 181(17):3064-3081. PubMed ID: 38689378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.
    Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM
    Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.